72458-46-9

Basic information

• Product Name: (2R,3R,4R,5S)-1-benzyl-2-(hydroxymethyl)piperidine-3,4,5-triol
• Synonyms: (2R,3R,4R,5S)-1-benzyl-2-(hydroxymethyl)piperidine-3,4,5-triol;(2R,3R,4R,5S)-1-benzyl-2-(hydroxymethyl)piperidine-3,4,5-triol(WXC04219)
• CAS NO: 72458-46-9
• Molecular Formula: C₁₃H₁₉NO₄
• Molecular Weight: 253.29426
• Mol File: 72458-46-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2R,3R,4R,5S)-1-benzyl-2-(hydroxymethyl)piperidine-3,4,5-triol(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3R,4R,5S)-1-benzyl-2-(hydroxymethyl)piperidine-3,4,5-triol(72458-46-9)
• EPA Substance Registry System: (2R,3R,4R,5S)-1-benzyl-2-(hydroxymethyl)piperidine-3,4,5-triol(72458-46-9)

Safety Data

• Hazardous Substances Data: 72458-46-9(Hazardous Substances Data)

Upstream product

• 132198-14-2 N-Benzhydryl-1-deoxynojirimycin 
• 214342-01-5 (3aS,6R,7R,7aS)-5-Benzyl-6-hydroxymethyl-2,2-dimethyl-hexahydro-[1,3]dioxolo[4,5-c]pyridin-7-ol 
• 531515-01-2 (E)-ethyl (4S,5S)-4,5-dihydroxy-6-(4-methoxybenzyloxy)-hex-2-enoate 
• 129083-15-4 {(2S,3R)-3-[(4R,5S)-5-(4-Methoxy-benzyloxymethyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-oxiranyl}-methanol 
• 214342-03-7 (1R,2R)-2-Benzylamino-1-((4S,5S)-5-hydroxymethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-but-3-en-1-ol 
• 214342-00-4 (3aS,6R,7R,7aS)-5-Benzyl-2,2-dimethyl-6-vinyl-hexahydro-[1,3]dioxolo[4,5-c]pyridin-7-ol 
• 132352-47-7 (E)-3-((4S,5S)-5-((4-ethoxybenzyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)prop-2-en-1-ol 
• 132352-49-9 ethyl (E)-3-((4S,5S)-5-((4-methoxybenzyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)acrylate 
• 19130-96-2 1,5-dideoxy-1,5-imino-D-glucitol 
• 100-39-0 benzyl bromide 

Downstream Products

• 19130-96-2 1,5-dideoxy-1,5-imino-D-glucitol 
• 149302-60-3 N-benzyl-2,3,4,6-tetra-O-benzyl-1-deoxynojirimycin 
• 114040-86-7 N-benzyl-1,5-dideoxy-1,5-imino-4,6-O-isopropylidene-D-glucitol 
• 114040-90-3 N-benzyl-3-O-benzyl-1,5-dideoxy-1,5-imino-4,6-O-isopropylidene-2-O-(trifluoro-methyl)sulfonyl-D-mannitol 
• 114040-87-8 N-benzyl-1,5-dideoxy-1,5-imino-4,6-O-isopropylidene-2,3-di-O-(methylsulfonyl)-D-glucitol 
• 114040-91-4 2-azido-N-benzyl-3-O-benzyl-1,2,5-trideoxy-1,5-imino-4,6-O-isopropylidene-D-glucitol 
• 114040-93-6 2-acetamido-N-benzyl-3-O-benzyl-1,2,5-trideoxy-1,5-imino-4,6-O-isopropylidene-D-glucitol 
• 114040-92-5 (4aR,7S,8R,8aR)-5-Benzyl-8-benzyloxy-2,2-dimethyl-hexahydro-[1,3]dioxino[5,4-b]pyridin-7-ylamine 
• 114040-89-0 N-benzyl-3-O-benzyl-1,5-dideoxy-1,5-imino-4,6-O-isopropylidene-D-mannitol 
• 114040-88-9 N-benzyl-1,2,3,5-tetradeoxy-1,5-imino-4,6-O-isopropylidene-D-erythro-2-hexenitol 
• 105265-96-1 2-acetamido-1,2-dideoxynojirimycin 
• 114129-23-6 N-benzyl-1,5-dideoxy-1,5-imino-4,6-O-isopropylidene-D-mannitol 
• 149302-61-4 N-<(p-fluorophenoxy)ethyl>-2,3,4,6-tetra-O-benzyl-1-deoxynojirimycin 
• 69567-11-9 2,3,4,6-tetra-O-benzyl-1,5-dideoxy-1,5-imino-D-glucitol 

Relevant articles and documents

Gas-phase structure and conformation of the glycosidase and ceramide glucosyltransferase inhibitor N-benzyl deoxynojirimycin

The deoxynojirimycin (DNJ) family of imino sugars are glucose analogues with an NH group replacing the oxygen atom in the pyranose ring. They are powerful inhibitors of glycosidases and ceramide glucosyltransferases. The conformation of N-benzyl-DNJ, isol

Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections

Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

Use of alkylated iminosugars to treat multidrug resistance

Methods and compositions for preventing, reducing, or reversing multidrug resistance (MDR) during cancer chemotherapy in patients undergoing treatment with therapeutically effective amounts of chemotherapeutic agents are provided. The methods comprise administering an anti-MDR effective amount of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol iminosugar to a patient.